Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells That Modulates Mature Regulatory Dendritic...

Area of Science:

• Immunology
• Oncology
• Metabolic Reprogramming

Background:

• Chemotherapy efficacy relies on inducing anti-tumor immunity.
• Understanding chemotherapy's immune modulation is key for optimized treatments.

Purpose of the Study:

• To investigate how metronomic chemotherapy modulates anti-tumor immune responses.
• To elucidate the mechanisms behind metronomic chemotherapy-induced immune memory.

Main Methods:

• Metronomic chemotherapy administration in a tumor model.
• Analysis of T cell responses and dendritic cell activity.
• Investigation of metabolic reprogramming and molecular signaling pathways (ATF4, asparagine, AXL, PD-L1).

Main Results:

• Metronomic chemotherapy induced robust CD8+ T cell-dependent anti-tumor immune memory.
• Sustained ATF4 activation led to tumor cell metabolic reprogramming and increased asparagine release.
• Asparagine binding to AXL on mature regulatory dendritic cells (mregDCs) inhibited AXL activity and PD-L1 expression.
• Reduced PD-L1 on mregDCs promoted the generation of memory-like CD8+ T cells.

Conclusions:

• Metronomic chemotherapy effectively generates anti-tumor immune memory by modulating mregDCs.
• The pathway involving tumor cell stress, asparagine release, and mregDC reprogramming is critical for immune memory formation.
• This study provides a rationale for optimizing chemotherapy strategies by leveraging immune-modulating effects.